Search research articles
Contact Us
Filters
Showing results (141-150 of 227) with videos related to
Page
of 23
Sort By:
Cancer
|
February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program
Alexander Drilon, Anne A Eaton, Katja Schindler, et al.
Frontiers in Oncology
|
May 25, 2026
A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors
Aman Chauhan, Elise C Kohn, S Percy Ivy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
Anne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors
Julie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
September 8, 2017
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma
Julia Matsumoto, Brian F Kiesel, Robert A Parise, et al.
Leukemia & Lymphoma
|
April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
Rena Buckstein, John Kuruvilla, Neil Chua, et al.
Cancer Chemotherapy and Pharmacology
|
February 4, 2010
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
Brian S Choi, Dona B Alberti, William R Schelman, et al.
Pediatric Blood & Cancer
|
July 27, 2010
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study
Orren Beaty, Stacey Berg, Susan Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
Ramesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2020
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker
Anand Joshi, Jianxia Guo, Julianne L Holleran, et al.
Page
of 23
Search research articles
Search
Showing results (141-150 of 227) with videos related to
Sort By:
Page
of 23
Cancer
|
February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program
Alexander Drilon, Anne A Eaton, Katja Schindler, et al.
Frontiers in Oncology
|
May 25, 2026
A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors
Aman Chauhan, Elise C Kohn, S Percy Ivy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
Anne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors
Julie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
September 8, 2017
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma
Julia Matsumoto, Brian F Kiesel, Robert A Parise, et al.
Leukemia & Lymphoma
|
April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
Rena Buckstein, John Kuruvilla, Neil Chua, et al.
Cancer Chemotherapy and Pharmacology
|
February 4, 2010
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
Brian S Choi, Dona B Alberti, William R Schelman, et al.
Pediatric Blood & Cancer
|
July 27, 2010
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study
Orren Beaty, Stacey Berg, Susan Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
Ramesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2020
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker
Anand Joshi, Jianxia Guo, Julianne L Holleran, et al.
Page
of 23